Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy
BMEMat, EarlyView.This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma +9 more
wiley +1 more source
Geographic variation in statin use for complex acute myocardial infarction patients: evidence of effective care? [PDF]
, 2014 Reprinted with permission of publisher.BACKGROUND: Despite strong evidence to designate statin use for secondary prevention of cardiovascular disease (CVD) as "effective care," observational studies show that many patients with CVD do not receive statins.
Abd +16 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.The Clinical Pharmacogenetics Implementation Consortium (CPIC) has formally updated the SLCO1B1 allele functionality table based on new evidence. Notably, the alleles studied (SLCO1B1 *9, *31, *41) are enriched in the genomes of patients historically excluded from pharmacogenomics research.
Akinyemi Oni‐Orisan +6 more
wiley +1 more source
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial [PDF]
Diabetes & Metabolism JournalBackground It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting
Jie-Eun Lee +37 more
doaj +1 more source
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. [PDF]
, 2016 OBJECTIVES: The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. BACKGROUND: Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart ...
Cooper, Lawton S. +13 more
core +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
The effects of atorvastatin in mustard gas exposed patients with chronic obstructive pulmonary disease: A randomized controlled trail [PDF]
Background: Statins have anti-inflammatory effects in patients with chronic obstructive pulmonary disease. This study designed to evaluate the effects of atorvastatin on serum highly sensitive C-reactive protein (hs-CRP) and pulmonary function in ...
قانعی, مصطفی +4 more
core
SAFETY EVALUATION OF STATIN IN YOGYAKARTA, INDONESIA [PDF]
, 2009 Background : The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-Co-A) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum Low-Density Lipoprotein cholesterol (LDL-c)concentrations.
Anni, Anni +3 more
core
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. [PDF]
, 2018 BackgroundEarly detection of adverse effects of novel therapies and understanding of their mechanisms could improve the safety and efficiency of drug development.
DeLisle, Robert K +8 more
core +2 more sources